What is the utility of immunotherapy in management of malignant peripheral nerve sheath tumors?
In particular, is there any data on the efficacy of Ipilimumab/Nivolumab?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
The correct answer would be "unknown" or "TBD". Enrollment on clinical trials, even broad phase 1 trials, would be encouraged in cases where SOC therapy has failed.
Join for free or sign in to see the full answer